Abstract
Clozapine, the drug of choice for treatment‐resistant schizophrenia in adults, has only limited research supporting its use in children and adolescents. Researchers, writing in the Journal of Child and Adolescent Psychopharmacology, found that 95% of pediatric patients admitted to a hospital on, or then placed on, clozapine were discharged on the medication, but stressed that the incidence of adverse effects was high, reinforcing the need for both accurate diagnoses and vigilant monitoring.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: The Brown University Child & Adolescent Psychopharmacology Update
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.